BBA
NBSE

Baker Bros. Advisors’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History

Baker Bros. Advisors’s Portfolio NBSE Stock Details NBSE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-926
Closed -$2.27M – 137
2015
Q4 		$2.27M Hold
926
– – 0.02% 103
2015
Q3 		$1.02M Hold
926
– – 0.01% 119
2015
Q2 		$930K Hold
926
– – 0.01% 117
2015
Q1 		$941K Buy
+926
New +$3.06M 0.01% 122

Other funds holding NBSE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
B
Bailard Foster City, California $4.35B AUM 23.57% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
ARTA
A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return
GBA
Garrison Bradford & Associates New York $88.4M AUM 15.86% 1-Year Est. Return

Baker Bros. Advisors's NBSE Position: Q1 2016 in Review

Baker Bros. Advisors sold out of NeuBase Therapeutics, Inc. Common Stock (NBSE) in Q1 2016, closing a stake of 926 shares — an estimated $2.27M sold.

Baker Bros. Advisors first reported a position in NBSE in Q1 2015 and held it in 4 quarters. The position peaked at $2.27M in Q4 2015. 50 funds tracked by Wall St. Rank hold NBSE as of Q1 2016.

  • Baker Bros. Advisors reported no remaining NeuBase Therapeutics, Inc. Common Stock position as of Q1 2016 after selling out during the quarter.
  • Baker Bros. Advisors sold 926 NeuBase Therapeutics, Inc. Common Stock shares in Q1 2016, an estimated $2.27M.
  • Baker Bros. Advisors first reported a position in NeuBase Therapeutics, Inc. Common Stock in Q1 2015 and held it in 4 quarters.
  • Baker Bros. Advisors's NeuBase Therapeutics, Inc. Common Stock position peaked at $2.27M in Q4 2015.
  • 50 funds tracked by Wall St. Rank held NeuBase Therapeutics, Inc. Common Stock as of Q1 2016.

Based on Baker Bros. Advisors's 13F filing for Q1 2016, filed 16 May 2016.